"With th[e] guidance issued today, the FDA is helping industry and investigators navigate the COVID-19 pandemic and help assess how to move forward with critical clinical trials."

Anand Shah,
Deputy Commissioner for Medical and Scientific Affairs
March 18, 2020

MyOwnMed ECOS System

For the Reordered Global Healthcare Landscape

THE STATUS OF DRUG DEVELOPMENT

There is an urgent need for creating new strategies for innovating clinical trial connectivity in a rapidly transforming health care environment. When bringing clinical trial patients to sites is facing limitations, we can help you bring the clinical trial to patients.

We bring extensive regulatory expertise and digital technology implementation experience together to create solutions that support de-centralized patient-centric clinical studies.

Our ECOS Platform provides remote-monitoring to maintain continuity in today's healthcare environment where extensive in-clinic assessments may not be desired or possible. We build and efficiently execute patient-centric clinical studies, capturing efficacy and effectiveness of data simultaneously.

Our next-generation lean technology is "plug-and-play" allowing for agile, rapid development and deployment of the ECOS System – where one platform and one portal can support multiple mobile, technology-enabled, studies. This allows for rapid patient recruitment, e-consent, optimized retention and the ability to bridge patients between in-clinic visits or for follow up studies.

THE FUTURE OF DRUG DEVELOPMENT

The MyOwnMed ECOS System represents a means to streamline clinical research processes, reducing time and costs associated with the current effort of traditional build and re-build one-off clinical trials. It all starts with building the right strategy – asking the right questions, then designing a digitally powered approach fit for purpose.

ECOS SYSTEM

Our digital strategies and technology platform are informed by years of regulatory and innovative clinical trial experience built to fulfill the vision of transformation that the FDA has outlined for next-generation clinical trials and valuable real-world insights needed for optimizing market access in an increasingly challenging marketplace.



MyOwnMed ECOS Platform

An Integrated Approach to Clinical Trials

With the ECOS Platform, our customers are able to achieve new levels of time and cost efficiency across the clinical research value chain. The ECOS Platform combines smart, agile study design and development, quick study start-up using data-driven patient stratification and our rapid research trial networks, and scalable HIPAA/GDPR and FDA compliant digital technology.



Our seamless multi-source data capture and integration through easily configurable workflows and direct-to-patient digital technology, presents a new de-centralized paradigm for lean and efficient clinical trials. It allows for capture of real-world evidence (RWE) to augment FDA filings and support market access strategy, simultaneously.

Results from our study design approach and platform technology can be seen in multiple forms. For example, in a recent industry study, using ECOS Mobile, we have achieved a significant reduction in study start-up time, execution, and increased enrollment.

ECOS PLATFORM
Implement remote monitoring of patients from portal

ECOS MOBILE APP
Patient download and enrollment with easy-to-use QR code

ECOS DATA
Brand, disease or drug diagnostics for single and multiple study formats

ECOS SYSTEM
Better patient engagement for study continuity

We are a team of experts with decades of experience in immunology, science, clinical trials, health care policy, and medical product regulation, regulatory policy, and science expertise spanning development of biomarker discovery and validation, advanced data mining and analytics, and extensive experience in clinical trials.

My Own Med, Inc.
info@myownmed.com
(240) 356-1008

myownmed.com